Physician profile
Christopher Arnold Hedquist
NPI 1043361843
$4,523.58
in general payments reported to CMS, 2019-2025
13 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $264 · 2021: $553 · 2022: $1,306 · 2023: $503 · 2024: $249 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,340.42 | 2019-2025 | Precision 1, Dailies Total1, Air Optix Color |
| Johnson & Johnson Vision Care, INC. | $929.88 | 2019-2025 | Acuvue |
| Abbvie INC. | $277.83 | 2022-2025 | |
| Glaukos Corporation | $273.61 | 2022-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $124.46 | 2024 | Xdemvy |
| Coopervision INC. | $111.57 | 2019-2025 | Myday Contact Lens |
| Apellis Pharmaceuticals, INC. | $91.59 | 2023 | Syfovre |
| Dompe US, INC. | $85.61 | 2023 | Oxervate |
| Rxsight INC | $76.99 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Allergan, INC. | $74.77 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $73.60 | 2021 | |
| Bausch & Lomb Americas INC. | $52.07 | 2025 | Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hedquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.